For Healthcare Professionals

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

clipboard-pencil

About the study

To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Age ≥ 18 years
  2. Willing and able to give written informed consent
  3. Have histologically or cytologically confirmed advanced or metastatic solid tumor
  4. There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy
  5. Able to swallow oral medication
  6. Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
  7. Adequate cardiovascular, hematological, liver, and renal function
  8. Willing to comply with all protocol-required visits, assessments, and procedures

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Previous treatment with a SHP2 inhibitor
  2. Documented PTPN11 mutations
  3. Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-601
  4. Received prior palliative radiation within 7 days of Cycle 1, Day 1
  5. Have primary central nervous system (CNS) disease or known active CNS metastases and/or carcinomatous meningitis
  6. Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
  7. Active, clinically significant interstitial lung disease or pneumonitis
  8. History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose of study treatment
  9. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO
  10. Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
  11. Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Advanced or Metastatic Solid Tumors

Age (in years)

18 - 99

Phase

Phase 1

Participants needed

200

Est. Completion Date

May 31, 2024

Treatment type

Interventional


Sponsor

Erasca, Inc.

ClinicalTrials.gov identifier

NCT04670679

Study number

ERAS-601-01

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.